How Much Does Bosulif Cost? — Save Up to 95% in Canada

At the US pharmacies in our data, the lowest listed discount-card price for Bosutinib is around $7,607.27. Prices vary by pharmacy, dosage, and pack size, so use the table above to compare specific options near you.

Yes — Cost Plus Drugs lists Bosutinib at roughly $466.67 per unit, a published price with no membership card or coupon involved. See the three-price comparison above for how that stacks up against discount-card pharmacies.

Canadian pharmacy listings in our data show Bosutinib priced from about $21.85 per tablet (converted to USD), before shipping. Pack size and pharmacy both affect the final total — see the Canada pricing table for specifics.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. In this case, our data shows the Canadian price coming in lower — but that isn't true for every drug, so it's worth checking each medication individually rather than assuming.

Your out-of-pocket cost for Bosulif with insurance will depend on your specific plan's formulary and benefit structure. Copay amounts vary widely, so it is best to contact your insurance provider for details. Your pharmacist can also help you compare your insurance copay against potential savings available through manufacturer coupons or other pharmacy discount programs, which may sometimes offer a lower price than your insurance plan.

No. Bosulif is the brand name for the active ingredient bosutinib. A generic equivalent (bosutinib) is not currently available on the market in the United States.

Bosulif is a brand-name, prescription oral medication used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). CML is a cancer of the bone marrow characterized by the uncontrolled production of abnormal white blood cells. Bosulif contains the active ingredient bosutinib, which is a tyrosine kinase inhibitor. It works by blocking specific abnormal proteins (tyrosine kinases) that signal the cancer cells to grow and multiply. This targeted action helps slow the overproduction of defective white blood cells. It is approved for use in both newly diagnosed patients and those whose disease has progressed after prior therapy. The medication is taken as a tablet once daily with food, with the exact dosage determined by your doctor based on your condition and treatment history.